1. Nature Japan
  2. Nature Biotechnology
  3. v32 n9
  4. 遺伝子治療の価格設定の特殊な例
Opinion and Comment

遺伝子治療の価格設定の特殊な例

Nature Biotechnology 32, 9 doi: 10.1038/nbt.3003

Gene therapy companies that pursue high, one-time payments for their products risk a backlash from payors. A better solution may lie in a pay-for-performance model.
Full text
PDF

目次へ戻る

advertisement
プライバシーマーク制度